SCHEMBL4769753

SCHEMBL4769753

COC(=O)c1sc2cc(F)ccc2c1C1CCNCC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.45
KCNH2 Q12809 1/20 0.45
RAB9A P51151 2/20 0.45
CTSS P25774 3/20 0.42
BCKDK O14874 1/20 0.40
TLR9 Q9NR96 1/20 0.40
TLR8 Q9NR97 1/20 0.40
CHRM2 P08172 2/20 0.39
CHRM1 P11229 2/20 0.39
CHRM3 P20309 2/20 0.39
HTR1A P08908 1/20 0.38
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
IKBKB O14920 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
TNF P01375 1/20 0.37
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4769747 0.99 HTR2A (0.44) HTR2AKCNH2RAB9ACTSSBCKDK
SCHEMBL912462 0.92 RAB9A (0.49) HTR2AKCNH2RAB9ACTSSBCKDK
SCHEMBL4792978 0.85 BCKDK (0.53) RAB9ACTSSBCKDKHTR1ASLC6A2
SCHEMBL4767198 0.83 CTSS (0.53) RAB9ACTSSBCKDKLMNAHPGD
SCHEMBL2610277 0.77 RAB9A (0.49) RAB9ACTSSBCKDKSMN1; SMN2KDM4E
SCHEMBL2428388 0.77 MAPK1 (0.40) RAB9ACTSSSLC6A3SMN1; SMN2KDM4E
SCHEMBL25208220 0.76 BCKDK (0.49) RAB9ABCKDKIKBKBSMN1; SMN2KDM4E
SCHEMBL31015992 0.76 BCKDK (0.49) RAB9ABCKDKIKBKBSMN1; SMN2KDM4E
SCHEMBL693361 0.76 BCKDK (0.60) RAB9ACTSSBCKDKSMN1; SMN2KDM4E
SCHEMBL912683 0.75 RAB9A (0.52) RAB9ABCKDKSMN1; SMN2KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1315492-B1 USE OF SUBSTITUTED PYRAZOLES FOR THE TREATMENT OF ALLERGIES ORTHO MCNEIL PHARM INC (US) 2008-07-30 EP disclosed
US-7265102-B2 Substituted pyrazoles ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2007-09-04 US disclosed
EP-1309592-B9 SUBSTITUTED PYRAZOLES ORTHO MCNEIL PHARM INC (US) 2007-02-28 EP disclosed
EP-1309592-B1 SUBSTITUTED PYRAZOLES ORTHO MCNEIL PHARM INC (US) 2006-04-26 EP disclosed
US-20050234102-A1 Substituted pyrazoles CAI HUI 2005-10-20 US disclosed
US-6951851-B2 Substituted pyrazoles CAI HUI 2005-10-04 US disclosed
US-6949540-B2 Substituted pyrazoles ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2005-09-27 US disclosed
US-6936603-B2 Substituted pyrazoles ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2005-08-30 US disclosed
US-20040044027-A1 Substituted pyrazoles CAI HUI (US) 2004-03-04 US disclosed
US-20030229075-A1 Substituted pyrazoles CAI HUI (US) 2003-12-11 US disclosed
US-20030225063-A1 Substituted pyrazoles ORTHO MCNEIL PHARMACEUTICAL, INC. 2003-12-04 US disclosed
US-20030225062-A1 Substituted pyrazoles ORTHO MCNEIL PHARMACEUTICAL, INC. 2003-12-04 US disclosed
US-6635633-B2 Substituted pyrazoles ORTHO-PHARMACEUTICAL, INC. 2003-10-21 US disclosed
US-6579896-B2 Immunology response; autoimmune disease ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-06-17 US disclosed
EP-1315492-A2 A METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES Ortho McNeil Pharmaceutical, Inc. (US) 2003-06-04 EP disclosed
EP-1309592-A2 SUBSTITUTED PYRAZOLES Ortho-McNeil Pharmaceutical, Inc. (US) 2003-05-14 EP disclosed
US-20020147189-A1 Method for treating allergies using substituted pyrazoles ORTHO MCNEIL PHARMACEUTICAL, INC. 2002-10-10 US disclosed
US-20020040019-A1 Substituted pyrazoles ORTHO MCNEIL PHARMACEUTICAL, INC. 2002-04-04 US disclosed
WO-2002020013-A2 A METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2002-03-14 WO disclosed
WO-2002014317-A2 SUBSTITUTED PYRAZOLES ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2002-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225062-A1 Substituted pyrazoles CTSS, CTSZ, CTSV HTR2A 4480/4885KCNH2 3779/4885RAB9A 651/4885
US-20030229075-A1 Substituted pyrazoles CTSS, CTSZ, CTSV HTR2A 4480/4885KCNH2 3779/4885RAB9A 651/4885
US-20020040019-A1 Substituted pyrazoles CTSS, CTSZ, CTSV HTR2A 4480/4885KCNH2 3779/4885RAB9A 651/4885
US-20040044027-A1 Substituted pyrazoles CTSS, CTSZ, CTSV HTR2A 4480/4885KCNH2 3779/4885RAB9A 651/4885
US-20030225063-A1 Substituted pyrazoles CTSS, CTSZ, CTSV HTR2A 4480/4885KCNH2 3779/4885RAB9A 651/4885
US-20020147189-A1 Method for treating allergies using substituted pyrazoles TSLP, IL33, HRH2 HTR2A 2085/4885KCNH2 1858/4885RAB9A 3831/4885
US-20050234102-A1 Substituted pyrazoles CTSS, CTSZ, CTSV HTR2A 4480/4885KCNH2 3779/4885RAB9A 651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.